CARDIEX LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.049 AUD | 0.00% |
|
-5.77% | -63.70% |
| 02/04 | Australian Shares Inch Down As Market Assesses RBA Policy Meeting Minutes | MT |
| 02/04 | Cardiex Marks Two Milestones Toward Wearable Biomarker Technology Commercialization; Shares Up 5% | MT |
Valuation
| Fiscal Period: Juni | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Capitalization 1 | 34.1 | 22.24 | 14.41 | - | - |
| Enterprise Value (EV) 1 | 34.1 | 22.24 | 16.51 | 16.41 | -7.285 |
| P/E ratio | -2.79 x | -1.05 x | - | - | - |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | - | - | 1.32 x | 0.82 x | 0.28 x |
| EV / Revenue | - | - | 1.52 x | 0.93 x | -0.14 x |
| EV / EBITDA | - | - | -2.14 x | -6.08 x | -0.3 x |
| EV / FCF | - | - | -1.38 x | -4.83 x | -0.31 x |
| FCF Yield | - | - | -72.7% | -20.7% | -325% |
| Price to Book | - | - | - | - | 0.49 x |
| Nbr of stocks (in thousands) | 1,10,004 | 1,43,466 | 2,94,175 | - | - |
| Reference price 2 | 0.3100 | 0.1550 | 0.0490 | 0.0490 | 0.0490 |
| Announcement Date | 31/08/22 | 31/08/23 | - | - | - |
1AUD in Million2AUD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: Juni | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net sales 1 | - | - | 10.9 | 17.6 | 52.2 |
| EBITDA 1 | - | - | -7.7 | -2.7 | 24.6 |
| EBIT 1 | - | - | -8 | -2.9 | 24.3 |
| Operating Margin | - | - | -73.39% | -16.48% | 46.55% |
| Earnings before Tax (EBT) 1 | - | - | -8.3 | -3.4 | 23.9 |
| Net income 1 | -11.38 | -19.06 | -8.3 | -3.4 | 23.9 |
| Net margin | - | - | -76.15% | -19.32% | 45.79% |
| EPS 2 | -0.1110 | -0.1470 | - | - | - |
| Free Cash Flow 1 | - | - | -12 | -3.4 | 23.7 |
| FCF margin | - | - | -110.09% | -19.32% | 45.4% |
| FCF Conversion (EBITDA) | - | - | - | - | 96.34% |
| FCF Conversion (Net income) | - | - | - | - | 99.16% |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 31/08/22 | 31/08/23 | - | - | - |
1AUD in Million2AUD
Estimates
Balance Sheet Analysis
| Fiscal Period: Juni | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net Debt 1 | - | - | 2.1 | 2 | - |
| Net Cash position 1 | - | - | - | - | 21.7 |
| Leverage (Debt/EBITDA) | - | - | -0.2727 x | -0.7407 x | - |
| Free Cash Flow 1 | - | - | -12 | -3.4 | 23.7 |
| ROE (net income / shareholders' equity) | - | - | - | - | 96.4% |
| ROA (Net income/ Total Assets) | - | - | - | - | 56.4% |
| Assets 1 | - | - | - | - | 42.38 |
| Book Value Per Share 2 | - | - | - | - | 0.1000 |
| Cash Flow per Share 2 | - | - | -0.0400 | -0.0100 | 0.0800 |
| Capex 1 | - | - | 0.3 | 0.3 | 0.3 |
| Capex / Sales | - | - | 2.75% | 1.7% | 0.57% |
| Announcement Date | 31/08/22 | 31/08/23 | - | - | - |
1AUD in Million2AUD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -63.70% | 95.23L | |
| +11.05% | 23TCr | |
| +10.94% | 19TCr | |
| +12.95% | 14TCr | |
| +25.79% | 11TCr | |
| +0.91% | 6.36TCr | |
| +6.74% | 5.13TCr | |
| +12.04% | 5.1TCr | |
| +8.12% | 4.33TCr | |
| +4.50% | 3.7TCr |
- Stock Market
- Equities
- CDX Stock
- Financials CardieX Limited